34771-04-5

Basic information

• Product Name: TRANS-4-(CARBOBENZOXYAMINO)CYCLOHEXANECARBOXYLIC ACID
• Synonyms: Z-1,4-TRANS-ACHC-OH;TRANS-4-BENZYLOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;TRANS-4-(CARBOBENZOXYAMINO)CYCLOHEXANECARBOXYLIC ACID;TRANS-4-(CBZ-AMINO)CYCLOHEXANECARBOXYLIC ACID;TRANS-1-(BENZYLOXYCARBONYL-AMINO)-CYCLOHEXYL-4-CARBOXYLIC ACID;Z-TRANS-4-AMINOCYCLOHEXANECARBOXYLIC ACID;Cyclohexanecarboxylic acid, 4-[[(phenylmethoxy)carbonyl]amino]-, trans- (9CI);Z-Trans-4-Amino
• CAS NO: 34771-04-5
• Molecular Formula: C₁₅H₁₉NO₄
• Molecular Weight: 277.32
• Product Categories: N-CBZ
• Mol File: 34771-04-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 217 °C
• Boiling Point: 484.7°C at 760 mmHg
• Flash Point: 246.9°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 3.32E-10mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.75±0.10(Predicted)
• CAS DataBase Reference: TRANS-4-(CARBOBENZOXYAMINO)CYCLOHEXANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-4-(CARBOBENZOXYAMINO)CYCLOHEXANECARBOXYLIC ACID(34771-04-5)
• EPA Substance Registry System: TRANS-4-(CARBOBENZOXYAMINO)CYCLOHEXANECARBOXYLIC ACID(34771-04-5)

Safety Data

• Hazardous Substances Data: 34771-04-5(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

InChI:InChI=1/C15H19NO4/c17-14(18)12-6-8-13(9-7-12)16-15(19)20-10-11-4-2-1-3-5-11/h1-5,12-13H,6-10H2,(H,16,19)(H,17,18)/t12-,13-

Upstream product

• 100-51-6 benzyl alcohol 
• 619-82-9 trans-hexahydroterephthalic acid 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 1885-14-9 phenyl chloroformate 
• 15177-67-0 trans-4-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 3399-22-2 dimethyl 1,4-cyclohexanedicarboxylate 

Downstream Products

• 873651-89-9 (1r,4r)-4-aminocyclohexanecarbonitrile 

Relevant articles and documents

Tricyclic compound and JAK inhibitor

Provided is a novel tricyclic compound which has JAK inhibitory activity and is especially useful for prophylaxis, treatment or amelioration of autoimmune diseases, inflammatory diseases and allergic diseases. A novel tricyclic compound which is represented by formula (I), formula (II) or formula (III) (wherein each of A1, A2 and A3 represents a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 represents a methylene group or the like; each of X1 and X3 represents O or NH; each of R1 and R3 represents a cyano C1-6 haloalkyl group or the like; and R2 represents an aromatic heterocyclic group), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer or the pharmaceutically acceptable salt.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.